Transform Your In-Licensing Activities with InnoLicense AI
In-licensing is a crucial strategy for pharmaceutical and healthcare companies to manage and optimize their portfolios for growth and stability. Decisions related to in-licensing often focus on expanding or strengthening a company’s presence within a specific technology domain or therapeutic area.
In-licensing is traditionally a labor-intensive and time-consuming process. It involves several complex stages, such as identifying potential technologies, conducting thorough due diligence, evaluating market potential, negotiating terms, and managing contracts. Each step requires vigilant attention to detail and significant manual efforts, often resulting in prolonged timelines and increased costs.
Ingenious e-Brain's Generative AI Solution “InnoLicense AI”
Ingenious e-Brain leverages generative AI to transform the in-licensing process, automating many of these critical tasks and significantly enhancing efficiency.
InnoLicense AI is a cutting-edge generative AI solution tailored specifically for the life sciences industry, enabling organizations to streamline and enhance their in-licensing activities. Here are the detailed features:
By integrating this tool, we have phenomenally reduced manual work, by ∼70%, and automated the most cumbersome processes, such as screening relevant documents, categorizing them under technical headers, and building balanced scorecards for identifying best fits with precision.
As with the traditional approach, we used to manually conduct opportunity assessments for in-licensing, which was exceedingly time-consuming. Recognizing this challenge, Ingenious e-Brain has developed InnoLicense AI, an innovative tool that revolutionizes the process.
InnoLicense AI is not just a tool; it’s an empowerment for organizations, equipping them with the ability to:
- Discover hidden opportunities: Leveraging advanced Generative AI and Large Language Models, InnoLicense AI scans vast amounts of scientific literature, patent databases, and other data sources to uncover potential licensing opportunities that might otherwise go unnoticed.
- Predict market trends: By analyzing historical data and current market signals, identifying white spaces, and mapping industrial challenges, InnoLicense AI can forecast emerging trends in the life sciences sector, helping organizations stay ahead of the curve and make informed strategic decisions.
- Identify key startups/SMEs/Academia with novel technologies: The AI tool methodically profiles and evaluates startups, small and medium-sized enterprises (SMEs), and academic research institutions to identify entities developing groundbreaking technologies. This enables companies to target collaborations and partnerships effectively.
- Prepare a balanced scorecard to identify best-fits: InnoLicense AI employs a comprehensive scoring system that evaluates potential licensing candidates against a set of tailored criteria or key performance indicators. This balanced scorecard approach ensures that organizations objectively assess and compare opportunities to determine the best strategic fits.
- Enhance due diligence: The AI-driven platform provides thorough and accurate due diligence reports, encompassing financial analysis, intellectual property evaluations, competitive landscape assessments, and impact analysis. This robust due diligence support further mitigates risks and enhances decision-making confidence.
- Accelerate deal-making: By automating the opportunity assessment process and providing actionable insights, InnoLicense AI significantly reduces the time and effort required to finalize targets. This acceleration supports deal-making processes, allowing organizations to swiftly capitalize on strategic opportunities.
InnoLicense AI embodies Ingenious e-Brain’s commitment to leveraging artificial intelligence and advanced technologies to drive innovation and efficiency in the life sciences industry.
Are you willing to further explore the capabilities of our proprietary tool for streamlining in-licensing practices and navigating the key business challenges enterprises face, particularly in the life science industry? Click the link below to schedule a prior meeting.
